Welcome to our dedicated page for Hutchmed (China) SEC filings (Ticker: HCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The HUTCHMED (China) Limited (HCM) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. HUTCHMED files annual reports on Form 20-F and submits current information on Form 6-K under the Securities Exchange Act of 1934. These filings often attach press releases and announcements that detail clinical, regulatory and corporate developments.
For a biopharmaceutical company focused on targeted therapies and immunotherapies, Form 6-K reports can be particularly important. Recent 6-Ks have included exhibits relating to Phase III clinical trial readouts such as the SACHI study of savolitinib plus TAGRISSO® in EGFR-mutated non-small cell lung cancer, initiation of global clinical development for the ATTC candidate HMPL-A251, and NDA acceptances with priority review for fanregratinib in intrahepatic cholangiocarcinoma and savolitinib in MET-amplified gastric cancer. Other 6-Ks have covered R&D update events, clinical data presentations at major congresses, and corporate governance matters.
Investors can use these filings to track pipeline progress, regulatory interactions and capital market disclosures. While the 6-Ks referenced here focus on attaching press releases, HUTCHMED’s broader SEC reporting framework also includes its Form 20-F annual report, which typically provides more comprehensive information on risk factors, research and development activities, and financial statements.
On Stock Titan, HCM filings are updated as new documents are released to EDGAR, and AI-powered tools summarize key points to make lengthy disclosures more accessible. Users can quickly see which filings relate to clinical milestones, such as completion of enrollment in the SAFFRON Phase III trial of ORPATHYS® and TAGRISSO®, or to business topics like board appointments and voting rights announcements. This page is a useful starting point for anyone analyzing how HUTCHMED’s oncology and immunology strategy is reflected in its official SEC communications.
HUTCHMED (CHINA) LIMITED filed a Form 6-K as a foreign private issuer, indicating that it uses Form 20-F for its annual reports. The filing mainly serves as a cover for two exhibits: an announcement and a press release, each relating to the appointment of an acting chief executive officer. The document is signed on behalf of the company by Chief Financial Officer Johnny Cheng, confirming the company’s authorization of this disclosure.